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A B S T R A C T
Aims: Mouse studies have established distinct monocyte subtypes that participate in the process of athero-
sclerotic lesion formation. The pro-inﬂammatory Ly6Chigh monocyte subtype actively contributes to murine
plaque progression and destabilization. Also in humans, diﬀerent peripheral monocyte subtypes have been
identiﬁed, of which the CD14+CD16− classical monocyte is suggested to display similar pro-atherosclerotic
properties as the murine Ly6Chigh subtype. We aimed to investigate if circulating CD14+CD16− classical
monocytes associate with characteristics of a vulnerable carotid atherosclerotic plaque and if they associate with
the risk of secondary adverse manifestations of atherosclerotic disease.
Methods and results: We enrolled 175 carotid endarterectomy patients of the Athero-Express biobank in our
study. Just prior to surgical procedure, blood was collected and peripheral blood mononuclear cells were iso-
lated. Characterization of monocyte subsets was performed by ﬂow cytometry. Plaque characteristics were semi-
quantitatively scored for the presence of fat, collagen, intraplaque hemorrhage and calciﬁcation. Vessel density,
smooth muscle cells and macrophages were assessed quantitatively on a continuous scale. All features of a
vulnerable plaque phenotype, including low amounts of collagen and smooth muscle cells, and increased fat
content, vessel density, intraplaque hemorrhage and plaque macrophages were not signiﬁcantly associated with
diﬀerential levels of peripheral classical CD14+CD16− monocytes or other monocyte subsets. Using Cox re-
gression models to evaluate the prognostic value of circulating monocyte subtypes, we found that total counts of
peripheral monocytes, as well as CD14+CD16− classical and other monocyte subtypes were not associated with
the risk of secondary cardiovascular events during 3 years follow-up.
Conclusion: Circulating classical CD14+CD16− monocytes do not associate with speciﬁc vulnerable plaque
characteristics. In addition, they do not predict secondary adverse manifestations. This suggests that in patients
with established carotid artery disease, the circulating monocytes do not reﬂect plaque characteristics and have
no value in identifying patients at risk for future cardiovascular events.
1. Introduction
The link between monocytes and atherosclerosis is well established.
Plaque macrophages primarily derive from inﬁltrating circulating
monocytes in early atherosclerosis, while they may also arise from local
macrophage proliferation during plaque progression [1]. Macrophages
play a pivotal role in plaque initiation, development and progression by
phagocytosis of (oxidized) LDL and the secretion of inﬂammatory
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cytokines [2–4]. In addition, dying foam cells form a major part of the
necrotic core, which is known to further enhance the inﬂammatory
response.
Experimental studies in mice show that circulating inﬂammatory
Ly6Chigh monocytes, the suggested equivalent of human classical
CD14+CD16− monocytes [4,5], contribute to the process of athero-
sclerotic lesion formation. Ly6Chigh monocytes attach to the damaged
endothelium, and upon arrest, they migrate through the endothelial
layer into the plaque, primarily involving the chemokine receptor CCR2
[6–8]. The Ly6Chigh monocytes can subsequently diﬀerentiate into in-
ﬂammatory M1 plaque macrophages, which are associated with a vul-
nerable plaque phenotype [6,9–11]. Ly6Clow monocytes patrol the
vascular endothelium, and upon plaque inﬁltration may be involved in
scavenging of lipids and dead cells [9,12]. The association between
Ly6Clow monocytes and atherosclerotic plaque development remains
inconclusive. On the one hand, low levels of Ly6Clow monocytes were
associated with increased atherosclerotic lesion size [13,14], but
showed no eﬀect on atherosclerosis development on the other hand
[15].
Since classical CD14+CD16− monocytes contribute to plaque pro-
gression and vulnerability they may hold value in predicting patients at
risk for CVD. However, existing data regarding the prognostic value of
circulating monocytes remain inconclusive. Some studies indicate that
monocytes have no prognostic value [16–19], whereas other studies
suggest that high monocyte counts associate with increased risk for
recurrent CVD events or mortality [20–23]. This may partly be ex-
plained by the fact that diﬀerent monocyte subsets exist with distinct
plaque modifying properties [3,4,24,25]. Indeed, high levels of classical
and intermediate monocytes have been associated with increased risk
for adverse manifestations in CVD patients [26–28]. Moreover, classical
monocytes are linked to the presence and severity of atherosclerosis
[29].
Thus, although it is evident that monocyte subsets play a divergent
role in CVD, the question whether circulating monocyte subsets in
humans do relate to plaque characteristics has to the best of our
knowledge not been comprehensively addressed before. Moreover,
prospective cohort studies examining the prognostic value of monocyte
subsets in CVD patients are limited. We took advantage of our unique
biobank enclosing elaborate information of both plaque composition
and occurrence of secondary adverse manifestations during three years
follow-up. We investigated whether classical monocytes associate with
atherosclerotic plaque characteristics and if they associate with the risk
of secondary CVD events during three years follow-up.
2. Materials and methods
2.1. Patient selection
The current study comprises 175 patients in a subset from the
Athero-Express biobank [30]. All patients undergoing carotid en-
darterectomy between 2009 and 2011 were included based on avail-
ability of PBMCs. In addition to the standard procedure, including an
extensive patient questionnaire and detailed histological plaque char-
acterization, peripheral blood mononuclear cells (PBMCs) were isolated
from blood that was drawn preoperatively. Isolated PBMCs were stored
in liquid nitrogen until further analyses were performed. Patient follow-
up was executed for three years or until the occurrence of a secondary
cardiovascular event (cardiovascular death, stroke, myocardial infarc-
tion, coronary intervention, peripheral intervention (including ampu-
tation)). All events were validated using health records kept by general
practitioners. The study protocol conforms to the Declaration of Hel-
sinki and has been approved by the Institution's ethics committee on
research on humans. All patients provided written informed consent.
2.2. PBMC isolation
Twenty ml blood was collected in Li-Heparin tubes, and a complete
blood cell proﬁle was determined by a general hematology cell counter
(Cell Dyn 1800 Abbott, Minesota, USA). PBMCs were isolated by Ficoll
gradient fractionation and stored in liquid nitrogen, as described pre-
viously [31], until further analyses were performed.
2.3. Flow cytometry
After gentle thawing from liquid nitrogen, the PBMCs were washed
with RPMI 1640 ((61,870,010, Gibco Carlsbad, CA, USA) supplemented
with GlutaMax (room temperature (RT)) containing 25 nM HEPES, 1%
penicillin/streptomycin and 2% Fetal Bovine Serum (FBS) (10270–106,
Gibco, Carlsbad, CA, USA)). Cells were kept on ice during the whole
procedure, unless stated otherwise. To obtain single cell suspensions,
PBMCs were gently ﬁltered over a 40 μm cell strainer (542,040, Greiner
bio-one), washed with RPMI again and centrifuged at 350 g for 5min at
4 °C. Subsequently, the cells were washed with cold PBS supplemented
with 2% FBS and 20mM EDTA, centrifuged at 350 g for 5min at 4 °C
and resuspended in cold PBS with 1% BSA. Then, the cells were in-
cubated with ﬂuorescent antibodies (Supplemental table 1) for 30min
at RT in the dark, washed with cold PBS and centrifuged at 350 g for
5min at 4 °C. Isotype controls are shown in Supplemantal Fig. 2. To be
able to exclude dead cells, the cells were incubated with ﬁxable via-
bility, eFluor506 (eBioscience) for 30min at RT in the dark. Then, cells
were washed with cold PBS with 1% BSA and measured on the ﬂow
cytometer (Gallios, Beckman Coulter, Fullerton, CA, USA). Gating
analyses of the ﬂow cytometry data were performed using Kaluza 1.3
software. We selected viable CD11B+CD115+ monocytes, and based on
the combination of forward - sideward scatter and CD14 and CD16
expression, we identiﬁed classical (CD14+CD16−), intermediate
(CD14+CD16+) and non-classical (CD14−CD16+) monocytes
(Supplemental ﬁg. 1). In addition, we measured the surface expression
of CCR2, CXC3CR1 and CD11B and CD31 at the diﬀerent monocyte
subsets.
2.4. Atherosclerotic plaque characterization
We performed a comprehensive analysis of the atherosclerotic
plaque composition, as described previously [30,32,33]. This analysis
includes a semi-quantitative assessment of fat deposition, collagen de-
position, intraplaque hemorrhage and calciﬁcation. Vessel density,
smooth muscle cells (SMC's), and plaque macrophages were quantita-
tively determined on a continuous scale. In addition, we stained sec-
tions for M1 macrophages.
2.5. Immunostaining for M1 macrophages (iNOS)
For immunostaining, a subset of 50 athero express paraﬃn sections
were deparaﬃnized before endogenous peroxidase quenching and heat-
induced epitope retrieval (citrate buﬀer for Antigen Retrieval, Vector
Laboratories; H-3300). After blocking, slides were incubated with anti-
iNOS (Abcam; 15,323; 1:75) antibody binding followed by incubation
with anti-rabbit secondary antibody (klinipath; DPVR-HRP). Thereafter
visualization was performed with ImmPact Amec red (Vector labora-
tories; SK-4285) followed by a counterstain with hematoxylin.
2.6. Analysis of plaque composition
All stained sections are examined microscopically and digitally
stored. Two observers independently semi-quantitatively scored all
diﬀerent stainings. The relative lipid core size was estimated visually as
a percentage of total plaque area with the use of H&E and picrosirius
red stains, and divided into (1) ≤10% and (2)> 10% of the total
plaque area. Collagen deposition (picrosirius red) was divided into no,
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minor, moderate or heavy staining along the entire luminal border.
Intraplaque hemorrhage (H&E and ﬁbrin staining) was deﬁned as the
composite of plaque bleeding at the luminal side of the plaque as a
result of plaque disruption and intraplaque hemorrhage, and scored as
(1) absent or (2) present. Calciﬁcation (hematoxylin and eosin, H&E)
was scored as no, minor, moderate or heavy staining along the luminal
border or evident parts within the lesion. More speciﬁed deﬁnitions for
these categories have been described earlier (30) and for macrophages
these were deﬁned as 1) no/minor=CD68 staining with negative or
clusters with<10 cell present and 2) moderate/heavy= cell clusters
with> 10 cells present or abundance of positive cells. The alfa actin
(smooth muscle cell), CD68 (macrophage) and iNOS (M1 macrophage)
stainings are also analyzed quantitatively by computerized analyses.
For this, colour thresholds are set and adjusted until the computerized
detection meets the visual interpretation. The stainings are scored
quantitatively as percentage of stained area to total plaque area.
(AnalySiS version 3.2, Soft Imaging GmbH, Munster, Germany) as
percentage of plaque area [30,32–34]. Plaque microvessels were
stained with CD34 and quantiﬁed in 3 hotspots per plaque and scored
as an average amount of vessels per hotspot.
.
2.7. Statistical analyses
Normally distributed continuous variables were indicated as
means± standard deviations and compared by Student's t-tests or one-
way ANOVA. Non-normal distributed data were presented as medians
[inter-quartile ranges] and compared by Mann-Whitney U tests or
Kruskal-Wallis tests. Categorical variables were indicated as percen-
tages and compared by Chi-square or Fisher's exact-tests. Univariable
Cox proportional hazard models were used to study the association
between monocyte subsets and the occurrence of adverse cardiovas-
cular events over time. To obtain a normal distribution, we performed a
log transformation on the values of smooth muscle cells and plaque
macrophages. To analyze the correlation between peripheral monocytes
and vessel density, smooth muscle cells or plaque macrophages, linear
regression models were used. Data management and statistical analyses
were performed with RStudio [35] and the R software package [36]
(version 3.2.0., Vienna, Austria). P values< .05 were considered as
signiﬁcant. GraphPad Prism 7.02 software (La Jolla, CA, USA) was used
to produce the graphs.
3. Results
3.1. Patient characteristics
The current subcohort of the Athero-Express biobank comprised 175
patients with severe carotid atherosclerosis, undergoing carotid en-
darterectomy. During three years of follow-up, 55 of the 175 patients
(31%) experienced a secondary adverse cardiovascular event. The
median age of the patients was 71 years and 63.4% was male. Other risk
factors, clinical manifestations, medication use and laboratory para-
meters are depicted in Table 1 for all patients, and also stratiﬁed by
occurrence of secondary adverse CVD events. Since the clinical mani-
festations (asymptomatic and symptomatic) were comparable among
patients regarding circulating monocyte subset counts (Table 2), and
also between patients with and without secondary adverse events, we
included all patients undergoing carotid endarterectomy in the current
analyses. In addition, because the circulating monocyte subtypes did
not diﬀer between males and females (Table 2), we chose to evaluate
their association with plaque characteristics and secondary CVD events
in males and females together.
3.2. Circulating monocyte subsets
In the current study, patients have median monocyte values of
10.8% [inter-quartile range (IQR) 9.3–12.3]. Absolute monocytes
counts were approximately 800 cells/μl (IQR 600–1000 cells/μl). On
average, classical CD14+CD16− monocytes represented 89.2%, inter-
mediate CD14+CD16+ monocytes 4.8%, and nonclassical
CD14−CD16+ monocytes 5.9% of the total monocyte pool
(Supplemental ﬁg. 3), which corroborates previous studies [24,25].
To explore which patient characteristics associated with the number
of circulating monocytes, monocyte counts were presented for the
presence or absence of diﬀerent patient characteristics (Table 2). The
classical monocyte counts negatively correlated with HDL levels
(p= 0.03; Table 2), and positively correlated with hsCRP levels
(p= 0.02). In addition, classical monocyte counts were higher in pa-
tients taking calcium antagonists (p= 0.04). Peripheral nonclassical
monocytes were lower in current smokers than nonsmokers
(p= 0.003), higher in patients on beta blockers (p=0.008), and in-
creased upon increasing BMI (p=0.02). No statistically signiﬁcant
associations with patient characteristics were identiﬁed for circulating
Table 1
Patients characteristics are depicted for all patients and stratiﬁed by occurrence
of secondary adverse CVD events during follow-up.
Overall
(n=175)
No events
(n=120)
Events
(n=55)
P
Risk factors
Age (years) 71.0
[63.0–78.0]
71.0
[63.0–78.0]
73.0
[63.5–79.0]
0.50
Sex (% male) 111 (63.4) 74 (61.7) 37 (67.3) 0.59
BMI 26.0
[23.6–29.1]
26.1
[23.5–29.3]
25.7
[23.6–28.6]
0.74
Current smoker (%) 62 (35.6) 42 (35.3) 20 (36.4) 1
Contralateral stenosis (%) 75 (48.4) 47 (44.8) 28 (56.0) 0.25
Diabetes mellitus (%) 45 (25.7) 32 (26.7) 13 (23.6) 0.81
Hypertension (%) 152 (86.9) 102 (85.0) 50 (90.9) 0.41
Hypercholesterolemia
(%)
107 (71.8) 74 (70.5) 33 (75.0) 0.72
CAD history (%) 63 (36.0) 42 (35.0) 21 (38.2) 0.81
PAOD history (%) 32 (18.3) 16 (13.3) 16 (29.1) 0.02
Clinical manifestations
Asymptomatic 27 (15.4) 15 (12.5) 12 (21.8)
Amaurosis fugax 29 (16.6) 19 (15.8) 10 (18.2)
Stroke 42 (24.0) 31 (25.8) 11 (20.0)
TIA 77 (44.0) 55 (45.8) 22 (40.0)
Medication
Statins (%) 142 (81.1) 96 (80.0) 46 (83.6) 0.72
Diuretics (%) 79 (45.1) 52 (43.3) 27 (49.1) 0.58
Beta blockers (%) 85 (48.6) 56 (46.7) 29 (52.7) 0.56
Calcium antagonists (%) 43 (24.6) 26 (21.7) 17 (30.9) 0.26
ACE-inhibitors (%) 58 (33.1) 37 (30.8) 21 (38.2) 0.43
Angiotensin-2 antagonists
(%)
46 (26.4) 30 (25.2) 16 (29.1) 0.72
Anticoagulants (%) 11 (6.3) 5 (4.2) 6 (10.9) 0.10
Aspirin (%) 142 (81.6) 100 (84.0) 42 (76.4) 0.32
Antiplatelets (%) 153 (87.9) 106 (89.1) 47 (85.5) 0.67
Laboratory parameters
Cholesterol (mmol/L) 4.0 [3.3–4.8] 4.0 [3.3–4.8] 4.0 [3.3–4.7] 0.67
HDL (mmol/L) 1.0 [0.9–1.2] 1.0 [0.9–1.3] 1.0 [0.9–1.2] 0.14
LDL (mmol/L) 2.1 [1.6–2.8] 2.0 [1.6–2.7] 2.2 [1.8–2.9] 0.16
hsCRP (μg/mL) 1.7 [0.7–3.6] 1.7 [0.7–3.1] 2.0 [0.7–4.8] 0.49
GFR MDRD (ml/min) 69.1 (18.4) 70.1 (17.6) 66.9 (20.1) 0.30
Values are presented as mean ± standard deviation for normal distributions,
number of patients (frequency in percentage) for categorical variables, and
median [inter-quartile range] for non-normal distributions. P values are cal-
culated using Students' t-tests, Chi-square tests, and Mann-Whitney U tests,
respectively. BMI indicates body-mass index; Contralateral stenosis, 50–100%
stenosis of the contralateral carotid artery; CAD history, history of Coronary
Artery Disease; PAOD, peripheral artery occlusive disease; Amaurosis fugax,
temporary loss of vision; ACE-inhibitors, angiotensin-converting-enzyme in-
hibitor; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP,
high-sensitivity C-reactive protein; GFR MDRD, Glomerular ﬁltration rate ac-
cording to ‘Modiﬁcation of Diet in Renal Disease’ formula.
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intermediate monocyte counts (Table 2).
3.3. Circulating classical monocytes do not associate with plaque
characteristics
To address the question if classical monocytes associate with a more
vulnerable plaque phenotype, we studied the number of monocytes in
relation to atherosclerotic plaque characteristics (A representative
overview of pictures for each plaque characteristic category is shown in
Fig. 1). However, we observed no diﬀerences in the numbers of classical
CD14+CD16− monocytes, nor intermediate CD14+CD16+ or non-
classical CD14−CD16+ monocytes in relation to fat deposition (< 10%
vs.> 10%), collagen deposition (no/minor vs. moderate/heavy), in-
traplaque hemorrhage (yes/no) or calciﬁcation (no/minor vs. mod-
erate/heavy) (Fig. 2). Next, we further speciﬁed the categories again
showing no diﬀerences in the numbers of classical CD14+CD16−
monocytes, nor intermediate CD14+CD16+ or nonclassical
CD14−CD16+ monocytes in relation to fat deposition (3 cate-
gories: < 10%, 10–40% and≥ 40%, Supplemental ﬁg. 4)), collagen (4
categories: no, minor, moderate and heavy, Supplemental ﬁg. 5)) and
calciﬁcation (categories: no, minor, moderate and heavy, Supplemental
ﬁg. 6). In addition, we found no association between circulating
monocytes and high plaque vessel density (Fig. 3) or decreased num-
bers of smooth muscle cells (Fig. 4), which have been linked to a more
vulnerable plaque phenotype.
Since plaque macrophages are thought to derive –at least partly–
from circulating monocytes, we studied the association between cir-
culating monocytes and plaque macrophages. Absolute counts of total
monocytes or classical monocytes were not associated with macrophage
plaque content (R2=0.01, p= 0.24) and (R2=0.00, p= 0.46), re-
spectively (Fig. 5A-B). On the other hand, statistically signiﬁcant,
though weak negative correlations were observed for absolute counts of
intermediate (R2=0.04, p=0.02) and nonclassical (R2=0.06,
p < 0.01) monocytes with plaque macrophages (Fig. 5C-D). Next, we
assessed if an association with plaque iNOS content, a speciﬁc marker
for M1 macrohages. Plaque M1 macrophage content showed a weak,
non signiﬁcant correlation (R2=, p= 0.18) with plaque iNOS area
(Fig. 6A). When assessing the circulation monocytes, neither the total
pool nor the speciﬁc subsets associate to plaque M1 macrophages
(Fig. 6B-E).
Because monocyte migration, activation and plaque inﬁltration has
been described to be crucially dependent on the presence of surface
receptors like CCR2, CD11B and CXCR3 in mouse studies [6–8], we also
analyzed the association between monocyte surface expression of these
Table 2
The monocyte subset counts are depicted in relation to the presence or absence of patient characteristics.
Classical monocytes Intermediate monocytes Nonclassical monocytes
(cells/uL) (cells/uL) (cells/uL)
Categorial variables Risk factor present Risk factor present Risk factor present
Risk factors Yes No Yes No Yes No
Male sex 688 [497, 837] 656 [537, 770] 33 [18, 45] 31 [19, 50] 42 [25, 61] 38 [27, 58]
Current smoker 708 [554, 929] 644 [481, 810] 26 [18, 42] 33 [18, 49] 35 [19, 46] 43 [28, 65] **
Contralateral stenosis 663 [491, 828] 656 [481, 802] 28 [19, 46] 32 [17, 47] 41 [26, 56] 39 [24, 63]
Diabetes mellitus 722 [602, 1030] 656 [494, 799] 35 [24, 55] 30 [17, 46] 45 [32, 62] 39 [25, 60]
Hypertension 669 [505, 821] 631 [552, 848] 31 [17, 47] 35 [25, 47] 42 [25, 61] 32 [26, 45]
Hypercholesterolemia 672 [537, 825] 647 [475, 808] 32 [17, 45] 37 [22, 50] 43 [27, 60] 37 [21, 63]
CAD history 698 [557, 820] 656 [473, 832] 36 [17, 50] 28 [19, 44] 47 [27, 61] 37 [25, 60]
PAOD history 702 [554, 810] 659 [505, 830] 34 [17, 57] 32 [19, 47] 53 [28, 61] 39 [25, 60]
Medication use Yes No Yes No Yes No
Statins 679 [537, 839] 625 [434, 765] 33 [19, 48] 29 [15, 42] 42 [26, 62] 31 [23, 44]
Diuretics 663 [472, 772] 669 [543, 931] 29 [18, 44] 33 [19, 50] 40 [26, 60] 42 [24, 61]
Beta blockers 657 [503, 826] 700 [536, 826] 31 [18, 46] 32 [18, 48] 46 [31, 63] 36 [22, 51] **
Calcium antagonists 733 [605, 940] 644 [471, 812] * 36 [16, 68] 31 [19, 44] 42 [34, 63] 40 [25, 60]
ACE inhibitors 663 [475, 760] 670 [520, 836] 33 [22, 50] 31 [17, 46] 41 [25, 64] 39 [25, 60]
Angiotensin-2 antagonists 719 [530, 883] 649 [508, 820] 30 [16, 47] 32 [18, 48] 42 [31, 60] 39 [24, 61]
Anticoagulants 755 [640, 839] 663 [494, 822] 24 [19, 37] 32 [18, 48] 45 [40, 70] 39 [25, 60]
Aspirins 659 [487, 805] 756 [556, 867] 32 [17, 48] 31 [19, 42] 39 [25, 60] 45 [29, 78]
Antiplatelets 666 [497, 825] 684 [589, 832] 32 [18, 47] 28 [19, 59] 39 [25, 60] 56 [37, 86]
Clinical manifestations
asymptomatic 677 [472, 909] 30 [21, 62] 47 [27, 60]
occular 625 [463, 774] 31 [21, 39] 39 [24, 64]
stroke 657 [530, 919] 34 [19, 51] 43 [31, 67]
TIA 672 [549, 799] 30 [14, 44] 40 [23, 57]
Continuous variables
Risk factors
Age (per 1 year increase) −2.16 [−6.47, 2.16] 0.16 [−0.26, 0.58] 0.36 [−0.1, 0.81]
BMI (per unit increase) 2.25 [−6.74, 11.24] 0.21 [−0.67, 1.09] 1.12 [0.17, 2.06] *
Laboratory parameters
Cholesterol (per mmol/L increase) −38.28 [−78.35, 1.79] 1.01 [−3.15, 5.17] −3.98 [−8.42, 0.47]
HDL (per mmol/L increase) −167.82 [−320.22, −15.42] * 1.25 [−14.64, 17.15] −15.07 [−32.03, 1.89]
LDL (per mmol/L increase) −24.01 [−72.61, 24.59] 3.99 [−1.17, 9.15] −1.67 [−7.23, 3.9]
hsCRP (per μg/mL increase) 0.65 [0.09, 1.2] * 0.05 [−0.01, 0.1] 0.03 [−0.03, 0.09]
GFR MDRD (per ml/min increase) 2.06 [−0.32, 4.44] −0.1 [−0.33, 0.13] −0.04 [−0.29, 0.22]
Values are presented as median [inter-quartile range] for categorical variables, and beta [95% conﬁdence interval] for continuous variables. BMI indicates body-mass
index; CAD history, history of Coronary Artery Disease; PAOD, peripheral artery occlusive disease; Amaurosis fugax, temporary loss of vision; ACE-inhibitors,
angiotensin-converting-enzyme inhibitor; Contralateral stenosis, 50–100% stenosis of the contralateral carotid artery; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; hsCRP, high-sensitivity C-reactive protein; GFR MDRD, Glomerular ﬁltration rate according to ‘Modiﬁcation of Diet in Renal Disease’ formula. P-
values were calculated using a one-way ANOVA or Kruskal-Wallis tests for categorical variables where appropriate, and linear regression models for continuous
variables. * indicates p < 0.05 and ** p < 0.01.
J.A.L. Meeuwsen et al. Journal of Molecular and Cellular Cardiology 127 (2019) 260–269
263
Collagen
N
o/
M
in
or
M
od
er
at
e/
H
ea
vy
Collagen (Polarized)Macrophages VSMC
<1
0%
>1
0%
N
o/
M
in
or
M
od
er
at
e/
H
ea
vy
N
o
Ye
s
IPH (HE) IPH (Fibrin)Fat Calcification
N
o/
M
in
or
M
od
er
at
e/
H
ea
vy
Vessel density
Minor
Heavy
A B
C D
E
Fig. 1. Representative pictures of the diﬀerent plaque characteristics of Athero Express Plaques. Plaque characteristics include (A) Macrophages Vascular Smooth
Muscle Cells (VSMC), (B) Collagen, displayed as Sirius Red staining under bright and polarized light and categorized on no/minor and moderate/heavy staining, (C).
Fat content, categorized on< 10% or≥ 10% fat and Calciﬁcation categorized on no/minor and moderate/heavy staining. (D) Intra plaque hemorrhage, displayed on
H&E and ﬁbrin stain and categorized on No and Yes. (E) Vessel density displayed by hotspots of CD34 staining and categorized on no/minor and moderate/heavy
stain.
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Fig. 2. Classical monocyte subsets are not associated with
vulnerable plaque characteristics. Absolute cell numbers of
classical, intermediate and nonclassical monocytes are not
associated with fat deposition (A) presence of collagen (B),
intraplaque hemorrhage (C) and calciﬁcation (D). For each
monocyte subtype, median and inter-quartile range is in-
dicated. Statistical signiﬁcance was considered as p < 0.05,
calculated with the Mann-Whitney U test (n=166).
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receptors and the number of plaque macrophages. However, we found
no association between monocyte surface expression of CCR2, CD11B,
and CXCR3 and plaque macrophages (Supplemental table 2).
3.4. Circulating monocytes do not associate with secondary cardiovascular
endpoints
We then investigated whether the sheer number of circulating
monocyte subsets diﬀered between patients who experienced a sec-
ondary cardiovascular event during follow-up as compared to patients
who did not. Classical monocyte numbers were comparable among
patients with secondary events as compared to patients without
(median 670 [IQR 475–805] vs. 668 [536–864] cells/μL, p=0.59) as
were the numbers of intermediate (28 [19–46] vs. 33 [17–47],
p= 0.62) and nonclassical (39 [25–60] vs. 40 [25–61], p= 0.74)
monocytes (Fig. 7).
To investigate if monocyte subsets associated with the risk of sec-
ondary adverse manifestations over time, we performed univariable
Cox proportional hazard regression analyses. Circulating monocytes
were not associated with the risk of secondary events during follow-up
in univariable Cox regression analyses (Supplemental table 3).
4. Discussion
In the current study, we investigated the role of monocyte subsets in
association to the plaque phenotype, and in relation to recurrent ad-
verse CVD events in a patient cohort with advanced atherosclerotic
disease. We observed no association between classical CD14+CD16−
monocytes and plaque characteristics. In addition, we found that
monocyte subsets could not prognosticate secondary CVD events during
three years of follow-up.
First, we addressed the question if circulating classical monocytes
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Fig. 6. Plaque M1 macrophage content weakly associates with the number of plaque macrophages, but not to circulating monocytes. A weak correlation between
plaque M1 macrophages and CD68 plaque macrophage content was observed (A). No correlation was observed between total monocyte count (B), classical (C)
intermediate (D) and nonclassical monocytes (E) and plaque M1 macrophages.
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were related to atherosclerotic plaque phenotype. In contrast to their
role in experimental mice studies, in the current study in patients with
an advanced stage of atherosclerotic disease, classical monocytes were
not associated with characteristics of a vulnerable plaque phenotype. In
agreement with our study, a recent study using optical coherence to-
mography also showed no association between classical monocytes and
vulnerable plaque characteristics, including thickness of the ﬁbrous
cap, arc of lipid core and plaque calciﬁcation in UAP and STEMI pa-
tients [37]. However, absolute numbers of intermediate monocytes
were inversely correlated with thickness of the ﬁbrous cap and posi-
tively correlated with arc of lipid core [37]. In another study in patients
with carotid and systemic atherosclerosis, researchers used ultra-
sonography to determine plaque neovascularization. They observed
that patients with grade 1 or grade 2 neovascularization had higher
levels of classical monocytes (464 or 482 cells/μl, respectively) as
compared to patients without intraplaque neovascularization (406
cells/μl) [29]. However, contrasting results were obtained in a study
where asymptomatic patient with carotid plaque neovascularization
had lower levels of classical monocytes (255 cells/μl) than patients
without (310 cells/μl). The discrepancy between these studies and our
current study might be explained by the diﬀerence in study popula-
tions, and the diﬀerent techniques used for intraplaque vessels. Thus,
the exact association between classical monocytes and plaque neo-
vascularization remains to be further investigated [38].
In addition, we questioned if monocyte subsets reﬂect the presence
of plaque macrophages. We observed no association between circu-
lating classical CD14+CD16− monocytes and plaque macrophages, and
a statistically signiﬁcant, but weak correlation between peripheral in-
termediate CD14+CD16+ and nonclassical CD14+CD16− monocytes
and plaque macrophages, which might indicate that in advanced
atherosclerosis the peripheral monocytes only marginally contribute to
the intraplaque macrophage pool. As plaque macrophages encompass
diﬀerent subsets as well we performed immunohistochemistry staining
for inﬂammatory M1 macrophages and immune regulatory M2 mac-
rophages. Unfortunately, in our hands we were unable to reliably stain
for M2 macrophages in our plaque material. Despite the fact that M1
macrophages have been described as a marker for vulnerable plaques,
we observe a weak correlation between plaque macrophages (CD68 and
iNOS) and we were not able to associate plaque iNOS content to a more
vulnerable plaque phenotype (data not shown). M1 and M2 macro-
phages are overall equally present during plaque progression, but it has
been established that M1 macrophages are more abundantly present in
the shoulder region of the plaque (Stöger et al. Atherosclerosis. 2012
Dec; 225(2):461–8.). Unfortunately, given the fact that we use carotid
endarterectomy specimens, it is very diﬃcult to assess regional diﬀer-
ences in iNOS content and as such we have not been able to assess M1
content in the shoulder region. Besides, murine studies have shown that
plaque macrophages display signs of plasticity [39,40] and local pro-
liferation [1]. Strikingly, local proliferation accounted for approxi-
mately 90% of the plaque macrophages in advanced murine plaques
[1]. Thus, although monocyte inﬂux is a crucial process in atherogen-
esis (as displayed by the fact that atherosclerosis is diminished in ab-
sence of chemokine receptors that facilitate monocyte traﬃcking
[6,7,10,11,41,42]), monocyte recruitment may be less important in
more advanced atherosclerotic plaques [43–46]. In line, our patient
population presents with advanced atherosclerotic plaques, where
monocyte inﬂux might be less pronounced.
We observed no prognostic value for total monocytes, nor for
monocyte subsets for the identiﬁcation of high risk patients. In patients
with coronary artery disease (CAD), diﬀerent studies observed diverse
associations regarding the prognostic value of total monocytes, i.e. no
risk [16–19] or increased risk [20–23] of CVD events and mortality.
Cross-sectional studies have indicated that mainly intermediate mono-
cytes are associated with CVD and plaque progression [24]. However,
because of the cross-sectional design of these studies, no straightfor-
ward conclusions can be drawn about the prognostic value for the oc-
currence of adverse cardiovascular events. Cohort studies assessing the
prognostic value of speciﬁc monocyte subsets are limited, but suggest
classical and intermediate monocytes to be predictive of CVD events
during follow-up [26–28]. In the current study, we found no diﬀerences
in monocyte subsets between patients with and without recurrent ad-
verse events. This discrepancy might be explained by the fact that pa-
tients in the current study are older, receive pharmaceutical treatment
and have more severe atherosclerosis than random aged Swedish sub-
jects [28] or patients undergoing elective angiography [26]. In addi-
tion, diﬀerences in clinical manifestations (i.e. patients undergoing
elective angiography [26], STEMI patients [27], or random older
Swedish subjects [28]), and follow-up time (2 years in the STEMI
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patients, up to 9 years in random Swedish subjects), may contribute to
the inconsistency between the studies.
4.1. Future perspectives
As we investigated the correlation between classical CD14+CD16−
monocytes and plaque vulnerability in a cross-sectional manner, it
would be interesting to see whether monocyte numbers can predict
plaque composition over time. A marker of plaque progression could for
example be a useful indicator for intervention in asymptomatic pa-
tients. In addition, since monocyte inﬂux is crucially involved in de-
veloping plaques, the association between peripheral monocyte subsets
and plaque phenotype merits further investigation in developing pla-
ques, rather than advanced atherosclerotic plaques. Recently, techne-
tium-99m labeled PBMCs were tracked in vivo, in CVD patients and
healthy controls. Interestingly, PBMCs accumulation could be visua-
lized in atherosclerotic plaques [47]. This approach might be used to
study monocyte traﬃcking in CVD patients in order to gain mechanistic
insights of monocyte plaque inﬁltration, to support the identiﬁcation of
vulnerable plaques, or to validate therapeutic interventions that target
inﬂammatory cells in CVD. Regarding the prognostic value of monocyte
subsets, it is important that the ﬁndings from the current study will be
replicated in large standardized cohort studies of CVD patients. Mean-
while, easily available risk markers, such as the Neutrophil To Lym-
phocyte ratio (NLR) [19,48–51], may be considered for short term
implementation, in order to enhance risk prediction and to prevent
hospitalization, secondary events and mortality.
In conclusion, classical monocytes do not associate with a vulner-
able plaque phenotype. In addition, we show that circulating monocyte
subsets have no prognostic value for secondary CVD manifestations in a
population of severe atherosclerotic patients. These results suggest that
circulating monocytes do not reﬂect plaque phenotype and have only
limited value in identifying patients at risk for future cardiovascular
events.
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